Aribio Lab

The company's core technological strength lies in its proprietary immune enhancement platforms, which are designed to significantly boost vaccine efficacy. These platforms include 'L-pampo,' an adjuvant that stimulates TLR2 and TLR3 immune receptors simultaneously, and 'Lipo-pam,' a particle formulation delivery technology. These technologies aim to induce more potent and balanced immune responses than conventional methods. A key innovation is the development of a proprietary messenger RNA (mRNA) delivery system, Lipoplex, which allows for room temperature storage and distribution, overcoming a significant logistical hurdle associated with LNP-based mRNA vaccines.

CHA Vaccine Institute's business model is centered on developing a pipeline of vaccine candidates and then seeking partnerships or licensing deals with larger pharmaceutical companies. A notable agreement includes a technology transfer of its L-pampo adjuvant to Aston Sci for use in a cancer vaccine candidate. The company's revenue streams are primarily tied to these licensing activities and the progression of its products through clinical trials. Its pipeline is robust, featuring prophylactic and therapeutic vaccines. Key candidates include a therapeutic vaccine for chronic Hepatitis B (CVI-HBV-002), which has advanced to Phase 2b clinical trials, a third-generation prophylactic Hepatitis B vaccine, and vaccines for herpes zoster and influenza. The company is also leveraging its platforms to develop cancer immunotherapies, with research showing its L-pampo adjuvant can enhance the anti-tumor effects of checkpoint inhibitors.

The institute operates within the global biopharmaceutical market, targeting significant medical needs like chronic Hepatitis B and Herpes Zoster. By focusing on platform technologies, CHA Vaccine Institute aims to reduce the time and cost of developing new treatments for a variety of diseases. The company has secured investments from firms such as UTC Investment, Helios Private Equity, Korea Development Bank, and InterVest.